About Stephen Brady
Stephen Brady is a president and chief executive officer, director at Claris Biotherapeutics.
Stephen Brady reports to the SEC as a director or officer of 3 public companies: Tempest Therapeutics (TPST), Atreca (BCEL) and Immune Design (IMDZ).
Stephen Brady first appears on SEC filings in 2014.
Experience
This experience comes from Stephen Brady's profile and from SEC filings. For roles taken from filings, the years are when the filings name Stephen Brady in the role, so the role may have started earlier or lasted longer.
Claris Biotherapeutics, Inc. Current
President & CEO (2026 – Present)
Director
2026 – Present · Half Moon Bay, CA
Develops eye treatments for people with sight-threatening corneal diseases.
BO
Biotechnology Innovation Organization Current
Board Member
2022 – Present
TI
Tempest Therapeutics, Inc.
President and CEO, director
Chief Executive Officer (2019 – 2026)
2019 – 2026 · Public company (TPST)
AI
Atreca, Inc.
Board and Audit Committee Member
2021 – 2024 · Public company (BCEL)
IC
Immune Design Corp.
EVP, Strategy & Finance
Executive Vice President, Strategy & Finance (2013 – 2019)
2013 – 2019 · Public company (IMDZ)
3I
3-V Biosciences, Inc.
Chief Business Officer
2010 – 2013
PI
Proteolix, Inc.
Vice President, Corporate Development
2007 – 2010
LI
Lexicon Pharmaceuticals, Inc.
Senior Corporate Counsel and Licensing
2001 – 2007
LL
Lazard Venture Advisors LP, Lazard Frères & Co. LLC
Vice President
2000 – 2001
ML
Morrison & Foerster LLP
Associate
1996 – 2000
Key Colleagues at Startups
The people Stephen Brady works with at each company, as listed on that company's latest Form D.
Claris Biotherapeutics, Inc. · Form D/A, Aug 12, 2026
Brian Baum
Chief Commercial Officer
MF
Meredith Fisher
Director
RD
Reza Dana
Director
Henry Rath
Chief Business Officer
KH
Kenneth Harrison
Director
MH
Matt Hobson
Director
MD
Michael Dybbs
Director
MR
Maha Radhakrishnan
Director
Susan Orr
Chief Medical Officer
Clarke Atwell
Co-Founder and Chief Operating Officer
MG
Marc de Garidel
Director